QUINCE THERAPEUTICS INC
QNCXNASDAQTrading Snapshot
- Day Range
- $30.68 – $31.49
- 52-Week Range
- $15.10 – $910.00
- Volume
- $3.39B
- Avg Volume
- $2.42B
- Shares Outstanding
- 278,408
- Next Earnings
- Oct 31, 2026
Fundamentals Snapshot
- Annual Revenue
- $986,134
- Last Q Revenue
- $256,689
- P/E Ratio
- -0.4
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-15.08
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +15.8%
Why Investors Own QNCX
- ✓High-growth profile — revenue up +53.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 63% gross margin and 13% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
QUINCE THERAPEUTICS INC
QNCX
StockOtter · stockotter.spaceAbout QUINCE THERAPEUTICS INC
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript
Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript
Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for se
Quince Therapeutics to Participate in September 2026 Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for se
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
SOUTH SAN FRANCISCO, Calif. , June 30, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for se